Media about us

01 August 2014

12 Industry-Venture Fund Alliances: 2014 Edition

Genetic Engineering & Biotechnology News (GEN)

For companies struggling with R&D costs, VC firms can be saviors. It helps to have a friend. And for several pharma giants scrambling to cut R&D costs, those friends are venture capital firms that co-invest in startups whose new drugs and platform technologies appear attractive. In some cases, these pharma-venture “alliances” launch the startups, using the expertise of VC firm partners and company executives. Following is a list of 12 such alliances announced in recent years, mostly by biopharma giants with venture capital firms and alliance between Rusnano and Domain Associates is on the first place by total size of funds. 

04 June 2014

Focusing on the journey, not the destination, however, taking the whole winner’s stand, is the Russia’s hallmark - Facbrice Egros

Pharmatsevtichesky Vestnik – Pharmaceutical Bulletin

NovaMedica’s leader Fabrice Egros told Oksana Baranova, Pharmatsevtichesky Vestnik – Pharmaceutical Bulletin correspondent, about how the expats visualize and estimate prospects of the Russian pharmaceutical market.

06 May 2014

LA BioMed woos deep pockets interested in its lifesaving research

Sandy Mazza, Daily Breeze

From iodine eyedrops that prevent blindness in children to cholesterol testing to early discoveries that led to in vitro fertilization, the Los Angeles Biomedical Research Institute has made innovative scientific breakthroughs with worldwide implications since 1962.

06 May 2014

Surgeon reports high patient satisfaction with hydrogel corneal inlay

Healio.com

Overall patient satisfaction is 98% after implantation with the Raindrop inlay, according to a surgeon here. 

23 April 2014

Advances in Presbyopia Correction

Roger F. Steinert, MD / Medscape

Hello. I'm Dr. Roger Steinert, Chair of Ophthalmology and Director of the Gavin Herbert Eye Institute at the University of California, Irvine. I just returned from the World Ophthalmology Congress, held this year in Tokyo, Japan, and had the opportunity to participate in several sessions on presbyopia treatments with intracorneal inlays.

10 April 2014

Domain Associates Unfazed By Biotech IPO Ups and Downs

Timothy Hay, Wall Street Journal

Biotechnology stocks have had a rollercoaster experience on the public markets this year, with the sector taking a major hit in recent weeks after a long run-up.

05 April 2014

Duke spinout Regado files to raise up to $69M in new offering

Jason deBruyn, Triangle Business Journal

Duke University spinout Regado Biosciences has filed notice to sell new shares on the open market.

28 March 2014

Syndax Plots $69M IPO For Cancer Drug’s Stretch Run

Ben Fidler, Xcomony

Syndax Pharmaceuticals raised about $27 million in private financing last year to gear up for a late-stage clinical trial. Now, on the doorstep of that lengthy, 600-patient study, the Waltham, MA-based company is looking to Wall Street to get it to the finish line.

27 March 2014

SIFI and NovaMedica link up to market eye care products in Russia

ThePharmaLetter

Italian developer of innovative eye care solutions SIFI SpA Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS. Financial terms of the collaboration were not disclosed.

05 February 2014

NovaMedica and Skolkovo Foundation to build a research centre

Kavita Rainova, IHS Global Insight Daily Analysis

NovaMedica's (Russia) research unit, NovaMedica Innotech, has entered into an agreement with Russian agency Skolkovo Foundation for the creation of research centre at technopark Skolkovo. According to the report by news website Pharmvestnik, the research centre is to include biochemical, analytical, and pharmaceutical laboratories with an experimental production of dosage forms.